Nasdaq:TYRA
Tyra Biosciences, Inc.
A pre-revenue biotech firm utilizing a unique T-cell platform to develop next-generation cancer immunotherapies.
Key Metrics
Investment Thesis
Bull Case
The stock offers high-risk, high-reward potential if any of its clinical candidates receive FDA approval and demonstrate significant efficacy in oncology trials. The strong cash position of $93M provides a runway to execute on the pipeline without immediate need for further dilutive fundraising, assuming successful trial outcomes.
Bear Case
The company is burning through capital at an unsustainable rate with operating losses exceeding $86M while generating zero revenue from commercial sales. Without imminent positive clinical data or a major strategic partnership announcement, the current cash burn trajectory poses an existential threat to shareholder value.
About Tyra Biosciences, Inc.
Tyra Biosciences is a clinical-stage biotechnology company focused on developing novel therapeutics for cancer immunology and inflammation. The company leverages its proprietary T-cell technology platform to advance candidates through clinical development, aiming to transform outcomes in oncology and inflammatory diseases.
Analysis
Management Discussion
Recent financial performance shows aggressive scaling of R&D efforts with $80.1M spent on research and development alongside $24.1M in general and administrative expenses. Despite a massive cash infusion of $202.1M from financing activities, the company still recorded a net loss of -$86.5M for 2024, indicating that operating cash burn remains high even with substantial equity raises.
Industry Overview
The biotechnology industry is characterized by high barriers to entry and significant capital requirements for drug development, where companies often operate years before achieving profitability. Investors in this sector must navigate the volatility of clinical trial outcomes and regulatory approvals that can drastically alter a company's valuation overnight.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Revenue | $0 | $0 | $0 |
| Cost of Revenue | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 |
| Operating Expenses | $58.9M | $79.9M | $104.2M |
| Operating Income | $-58.9M | $-79.9M | $-104.2M |
| R&D | $43.0M | $62.5M | $80.1M |
| G&A | $15.9M | $17.4M | $24.1M |
| Stock-Based Comp | $10.6M | $13.5M | $22.8M |
| D&A | $296.0K | $353.0K | $519.0K |
| Depreciation | $296.0K | $400.0K | $500.0K |
| Other OpEx | $0 | $0 | $0 |
| Non-Operating Income | $0 | $0 | $0 |
| Pre-Tax Income | $-58.9M | $-79.9M | $-104.2M |
| Income Tax | $2.0K | $0 | $0 |
| Continuing Ops | $-58.9M | $-79.9M | $-104.2M |
| Discontinued Ops | $0 | $0 | $0 |
| Net Income | $-55.3M | $-69.1M | $-86.5M |
| Minority Interest | $0 | $0 | $0 |
| Net to Common | $-55.3M | $-69.1M | $-86.5M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Current Assets | $257.3M | $211.7M | $347.5M |
| Cash & Equivalents | $251.2M | $58.0M | $92.0M |
| Prepaid Expenses | $6.1M | $8.2M | $6.0M |
| Other Current Assets | $0 | $145.5M | $249.5M |
| Long-Term Assets | $8.9M | $14.2M | $16.1M |
| PP&E (Net) | $1.1M | $1.6M | $1.7M |
| Other LT Assets | $7.8M | $12.6M | $14.4M |
| Total Assets | $266.2M | $225.9M | $363.6M |
| Current Liabilities | $5.7M | $15.3M | $14.6M |
| Accounts Payable | $1.1M | $4.7M | $590.0K |
| Current Leases | $140.0K | $280.0K | $412.0K |
| Other Current Liab | $4.4M | $10.4M | $13.6M |
| Long-Term Liabilities | $2.7M | $6.3M | $5.8M |
| LT Operating Leases | $2.5M | $6.2M | $5.8M |
| Other LT Liab | $169.0K | $46.0K | $3.0K |
| Total Liabilities | $8.4M | $21.6M | $20.4M |
| Shareholders' Equity | $257.8M | $204.3M | $343.2M |
| Retained Earnings | $-95.7M | $-164.8M | $-251.3M |
| AOCI | — | $381.0K | $770.0K |
| Total L&E | $266.2M | $225.9M | $363.6M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Net Income (CFO) | $-55.3M | $-69.1M | $-86.5M |
| Non-Cash Adjustments | $-5.6M | $6.8M | $17.3M |
| Working Capital Changes | $10.6M | $12.2M | $-575.0K |
| Cash from Operations | $-50.3M | $-50.1M | $-69.8M |
| Capital Expenditures | $559.0K | $770.0K | $664.0K |
| Cash from Investing | $-559.0K | $-144.6M | $-98.4M |
| Cash from Financing | $632.0K | $1.5M | $202.1M |
| FX Effect | $0 | $0 | $0 |
| Net Change in Cash | $-50.2M | $-193.2M | $34.0M |
| Beginning Cash | $302.4M | $252.2M | $59.0M |
| Ending Cash | $252.2M | $59.0M | $93.0M |
Frequently Asked Questions
How does Tyra Biosciences, Inc. make money?
The company's financials reflect a single primary business segment focused on clinical-stage drug development with no current commercial revenue, as all cash flow is directed toward research and development expenses totaling $80.1M.
What are the main risks for TYRA?
As a pre-revenue biotech, the company faces significant risk of clinical trial failure which could deplete its cash reserves entirely. Investors must consider the lack of diversified revenue streams and total reliance on successful fundraising or strategic partnerships to fund operations. The deepening operating losses, rising from -$55.3M in 2022 to -$86.5M in 2024, indicate accelerating burn rates that threaten liquidity.
What is TYRA's competitive advantage?
Tyra Biosciences possesses a proprietary T-cell platform that targets specific immune checkpoints, offering a differentiated mechanism of action compared to standard checkpoint inhibitors. The company maintains a lean balance sheet with over $92M in cash while managing minimal current liabilities of only $14.6M.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.